Compare AbbVie Inc (ABBV) vs Marathon Digital Holdings Inc (MARA) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

MARA Holdings trades at $12.95, up 4.44% today, but faces significant fundamental challenges with a net income margin of -234.83% and three consecutive quarterly earnings misses. The technical picture remains bearish with key resistance at $13-$14, while analyst sentiment is mixed with a 50% buy rating but a consensus price target of $16.60. Recent developments include the shipment of a hybrid energy storage prototype system from TAE Power Solutions (PRNewsWire, June 30, 2026) and ongoing pivot toward AI infrastructure.

Despite the bullish analyst consensus and potential from AI infrastructure expansion, MARA faces substantial execution risks amid persistent losses and negative cash flow from operations. The stock's valuation appears attractive on P/E (3.37) and EV/EBITDA (3.31) metrics, but profitability concerns and Bitcoin market volatility create significant downside risk for investors.